Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMRXNASDAQ:IRDNASDAQ:LSBNASDAQ:MRSN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMRXImmuneering$1.44+12.1%$1.41$1.00▼$3.83$51.82M-0.222.35 million shs631,660 shsIRDOpus Genetics$1.02+7.4%$0.91$0.65▼$1.56$46.39M0.06214,644 shs295,948 shsLSBLakeshore Biopharma$1.14+5.8%$1.70$1.01▼$11.20$10.61M0.6420,607 shs4,776 shsMRSNMersana Therapeutics$0.34+8.1%$0.37$0.26▼$2.83$42.39M1.322.52 million shs3.56 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMRXImmuneering0.00%+26.32%+13.39%-22.58%-8.28%IRDOpus Genetics0.00%+7.72%+34.23%-9.73%+101,999,900.00%LSBLakeshore Biopharma0.00%0.00%-13.57%-52.50%+113,999,900.00%MRSNMersana Therapeutics0.00%+6.65%-4.12%-41.56%-86.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMRXImmuneering2.8055 of 5 stars3.32.00.00.02.23.31.3IRDOpus Genetics2.0575 of 5 stars3.50.00.00.02.40.01.3LSBLakeshore Biopharma0.5816 of 5 stars0.05.00.00.00.00.80.6MRSNMersana Therapeutics3.968 of 5 stars3.52.00.04.13.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMRXImmuneering 2.50Moderate Buy$15.33964.81% UpsideIRDOpus Genetics 3.00Buy$7.33618.95% UpsideLSBLakeshore Biopharma 0.00N/AN/AN/AMRSNMersana Therapeutics 3.00Buy$5.201,428.96% UpsideCurrent Analyst Ratings BreakdownLatest LSB, MRSN, IMRX, and IRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/15/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$3.005/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/6/2025MRSNMersana TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $3.004/11/2025IRDOpus GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/10/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/1/2025IRDOpus GeneticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.004/1/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/24/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMRXImmuneering$320K161.94N/AN/A$3.09 per share0.47IRDOpus Genetics$10.99M4.22N/AN/A$2.20 per share0.46LSBLakeshore Biopharma$672.27M0.02N/AN/A$8.86 per share0.13MRSNMersana Therapeutics$40.50M1.05N/AN/A$0.31 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMRXImmuneering-$53.47M-$1.96N/AN/AN/AN/A-79.19%-69.08%8/5/2025 (Estimated)IRDOpus Genetics-$9.99M-$2.10N/AN/AN/A-324.45%-63.65%-56.94%N/ALSBLakeshore Biopharma-$61.09MN/A0.00∞N/AN/AN/AN/AN/AMRSNMersana Therapeutics-$171.67M-$0.59N/AN/AN/A-214.20%-401.37%-38.61%N/ALatest LSB, MRSN, IMRX, and IRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IRDOpus Genetics-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million5/15/2025Q1 2025MRSNMersana Therapeutics-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/A3/31/2025Q4 2024IRDOpus Genetics-$0.34-$1.27-$0.93-$1.27$11.10 million$3.40 million3/20/2025Q4 2024IMRXImmuneering-$0.42-$0.58-$0.16-$0.58N/AN/A3/3/2025Q4 2024MRSNMersana Therapeutics-$0.16-$0.11+$0.05-$0.11$7.71 million$16.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMRXImmuneeringN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ALSBLakeshore BiopharmaN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMRXImmuneeringN/A7.997.99IRDOpus GeneticsN/A6.636.63LSBLakeshore Biopharma0.131.170.90MRSNMersana Therapeutics13.352.352.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMRXImmuneering67.65%IRDOpus Genetics14.97%LSBLakeshore Biopharma52.64%MRSNMersana Therapeutics93.92%Insider OwnershipCompanyInsider OwnershipIMRXImmuneering25.00%IRDOpus Genetics6.60%LSBLakeshore BiopharmaN/AMRSNMersana Therapeutics13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMRXImmuneering6035.99 million23.29 millionNot OptionableIRDOpus Genetics1445.48 million29.49 millionN/ALSBLakeshore Biopharma7739.31 millionN/AN/AMRSNMersana Therapeutics150124.63 million108.96 millionOptionableLSB, MRSN, IMRX, and IRD HeadlinesRecent News About These CompaniesMersana Therapeutics (NASDAQ:MRSN) Given New $10.00 Price Target at Truist FinancialMay 18 at 2:33 AM | americanbankingnews.comMersana Therapeutics' (MRSN) "Buy" Rating Reaffirmed at GuggenheimMay 18 at 2:33 AM | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Mersana Therapeutics (NASDAQ:MRSN)May 17 at 3:15 AM | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call TranscriptMay 16 at 9:35 AM | insidermonkey.comQ1 2025 Mersana Therapeutics Inc Earnings CallMay 16 at 4:58 AM | uk.finance.yahoo.comMersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...May 16 at 4:58 AM | finance.yahoo.comMersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancerMay 15 at 11:58 PM | msn.comCORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsMay 15 at 1:57 PM | finance.yahoo.comCORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsMay 15 at 9:20 AM | globenewswire.comMersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue EstimatesMay 15 at 9:16 AM | zacks.comMersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsMay 15 at 8:56 AM | finance.yahoo.comMersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial ResultsMay 15 at 7:00 AM | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and IQVIA Holdings (IQV)May 9, 2025 | theglobeandmail.comWedbush Predicts Increased Earnings for Mersana TherapeuticsMay 9, 2025 | americanbankingnews.comMersana Therapeutics announces strategic cutbacks amid economic pressuresMay 7, 2025 | investing.comMersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADCMay 6, 2025 | fiercebiotech.comMersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast CancerMay 6, 2025 | globenewswire.com4,250,000 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Novo Holdings A SMay 3, 2025 | marketbeat.comMersana Therapeutics (MRSN) Expected to Announce Earnings on ThursdayMay 3, 2025 | marketbeat.comWhy Mersana Therapeutics, Inc.’s (MRSN) Stock Is Down 8.13%May 2, 2025 | aaii.comMersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual MeetingApril 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLSB, MRSN, IMRX, and IRD Company DescriptionsImmuneering NASDAQ:IMRX$1.44 +0.16 (+12.06%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.04%) As of 05/16/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Opus Genetics NASDAQ:IRD$1.02 +0.07 (+7.37%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.02 +0.00 (+0.49%) As of 05/16/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Lakeshore Biopharma NASDAQ:LSB$1.14 +0.06 (+5.84%) Closing price 05/16/2025 03:58 PM EasternExtended Trading$1.13 -0.01 (-0.79%) As of 05/16/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Mersana Therapeutics NASDAQ:MRSN$0.34 +0.03 (+8.14%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.34 0.00 (-0.32%) As of 05/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Savvy Investors Are Raising a Glass for Heineken Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
